Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H11NO2 |
| Molecular Weight | 129.157 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CCC(O)=O)C=C
InChI
InChIKey=PJDFLNIOAUIZSL-YFKPBYRVSA-N
InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)/t5-/m0/s1
| Molecular Formula | C6H11NO2 |
| Molecular Weight | 129.157 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
VIGABATRIN, R-(-)- is an inactive enantiomer of gamma-vinyl-gamma-aminobutyric acid. Vigabatrin exists as a 50/50 racemic mixture of two enantiomers. It is an irreversible inhibitor of the GABA-transaminase, the enzyme responsible for the catabolism of GABA, thus increasing the GABAergic transmission. This drug is mainly prescribed for the treatment of West syndrome, a deleterious pediatric epileptic syndrome also known as infantile spasms. The maximum and minimum plasma concentrations of vigabatrin at steady-state were lower for the S(+) than for the R(-) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(-) enantiomer in a patient affected with tuberous sclerosis who developed major agitation and aggression and in whom impaired renal function was diagnosed. The question remains of the potential toxicity of the high levels of the R(-) enantiomer. The placental uptake of the active S(+)-isomer from the maternal circulation exceeded that of the R(-)-isomer and this was reflected by a corresponding difference in placental tissue concentrations.
Originator
Sources: https://patents.google.com/patent/US3960927
Curator's Comment: Original Assignee: Richardson-Merrell Inc.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Determination of the R(-) and S(+)-enantiomers of vigabatrin in human plasma by ultra-high-performance liquid chromatography and tandem mass-spectrometry. | 2017-12-01 |
|
| A direct HPLC method for the resolution and quantitation of the R-(-)- and S-(+)-enantiomers of vigabatrin (gamma-vinyl-GABA) in pharmaceutical dosage forms using teicoplanin aglycone chiral stationary phase. | 2009-08-15 |
|
| Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. | 2000-02-18 |
|
| Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. | 1997-08 |
|
| Vigabatrin. Clinical pharmacokinetics. | 1992-10 |
|
| Passage of S(+) and R(-) gamma-vinyl-GABA across the human isolated perfused placenta. | 1992-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10737423
Rat: 150 mg/kg
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:45:14 GMT 2025
by
admin
on
Mon Mar 31 22:45:14 GMT 2025
|
| Record UNII |
ODN92S847A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ODN92S847A
Created by
admin on Mon Mar 31 22:45:14 GMT 2025 , Edited by admin on Mon Mar 31 22:45:14 GMT 2025
|
PRIMARY | |||
|
DTXSID30227925
Created by
admin on Mon Mar 31 22:45:14 GMT 2025 , Edited by admin on Mon Mar 31 22:45:14 GMT 2025
|
PRIMARY | |||
|
157018
Created by
admin on Mon Mar 31 22:45:14 GMT 2025 , Edited by admin on Mon Mar 31 22:45:14 GMT 2025
|
PRIMARY | |||
|
77162-51-7
Created by
admin on Mon Mar 31 22:45:14 GMT 2025 , Edited by admin on Mon Mar 31 22:45:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |